Taken together, we have demonstrated that aberrant PI3K signaling driven by amplification or activating mutations of PIK3CA or PIK3CB are able to shift p110 isoform dependency regardless of PTEN status across multiple prostate cancer models. Here, PTEN is linked to prostate carcinoma.